Welcome to the e-CCO Library!

P432: Patient perspectives on biosimilars: a European Federation of Crohn’s and Colitis Associations survey
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Peyrin-Biroulet*1, S. Lönnfors2, S. Danese3, X. Roblin4, L. Avedano5, M. Greco5

Created: Friday, 22 February 2019, 9:49 AM
P432: Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Matini, L.(1)*;Stokes, E.A.(2);Parra Mujica, F.(3);Kormilitzin, A.(4);Kantschuster, R.(1);Punj Sharda, A.(1);Dunbar, G.(1);Song, K.(1);White, L.(1);Travis, S.P.L.(5);Walsh, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P432: Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sebastian S.*1,2, Tzivinikos C.3, Drskova T.4, Hradsky O.4, Nair M.V.1,5, Sahnan K.6, Muhammed R.7, Devadason D.8, Parmar R.S.3, Crook K.6, Akbar A.6, Thomson M.5, Hart A.L.6

Created: Wednesday, 20 February 2019, 10:36 AM
P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Hoque1, S. Boccaletti2, A. Puenpatom3, C. Brown2, C. Black3, J. Roberts4, I. Rajkovic4, G. Milligan4

Created: Thursday, 30 January 2020, 10:12 AM
P433: Aetiologies of iron deficiency-related anaemia in German patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Aksan*1,2, E. Leventi1,3, K. Farrag1,3, I. Mavrommataki1,3, A. Dignass4, J. Stein1,3

Created: Friday, 22 February 2019, 9:41 AM
P433: Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Attara*1, R. Bailey2, B. Bressler3, J. Marshall4, R. Panaccione5, G. Aumais6

Created: Friday, 22 February 2019, 9:49 AM
P433: Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;D'Haens, G.(2);Seenan, J.P.(3);Caprioli, F.(4,5);Siegel, C.(6);Nakamura, M.(7);Wei, S.C.(8);Kligys, K.(9);Zhang, Y.(9);Zambrano, J.(9);Song, A.P.(9);Ferrante, M.(10);
Created: Friday, 14 July 2023, 11:05 AM
P433: Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

R.W.M. Pauwels*, A.C. De Vries, C.J. Van der Woude

Created: Thursday, 21 February 2019, 9:14 AM
P433: Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.
Year: 2022
Source: ECCO'22
Authors: Garcia-Alvarado, M.(1);Barrio, J.(2);Sierra-Ausin, M.(3);Arias, L.(4);Fernández-Salazar, L.(5);Fuentes Coronel, A.(6);Arias García, L.(7);García-Alonso, F.J.(8);García-Prada, M.(3);Legido, J.(4);Sánchez-Hernández, J.G.(9);Muñoz, F.(10);
Created: Friday, 11 February 2022, 3:52 PM
P433: Postsurgical recurrence in Crohn's disease. Multicenter study in the region of Murcia, Spain of GEMEII group
Year: 2017
Source: ECCO '17 Barcelona
Authors:

García Albert A.M.1, García-Paredes R.*2, Torrella Cortés E.3, Martinez-Jimenez T.4, Angel Rey J.M.4, García-Tercero I.2, Castillo Espinosa J.M.5, Torregrosa Lloret M.3, Chacόn Martínez S.3, Andreu Plaza J.6, Rodríguez Lozano A.2

Created: Wednesday, 20 February 2019, 10:36 AM
P433: Sex-based differences in response to tumor necrosis factor inhibitor induction therapy for ulcerative colitis: a pooled analysis of individual patient-level clinical trials data
Year: 2021
Source: ECCO'21 Virtual
Authors: Agrawal, M.(1);Petralia, F.(2);Tepler, A.(3);Durbin, L.(4);Reinisch, W.(5);Colombel, J.F.(1);Shah, S.(6,7);
Created: Wednesday, 2 June 2021, 4:12 PM
P434 Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Chaparro1, A. Garre1, M. Iborra2, M. Barreiro-de Acosta3, M.J. Casanova1, L. De Castro4, A. Fernández-Clotet5, J. Hinojosa6, M. Boscá-Watts7, D. Busquets8, A. López-García9, R. Lorente10, N. Manceñido11, T. Martínez12, D. Monfort13, J.L. Pérez-Calle14, A. Villoria15, T. Angueira16, F. Bermejo17, A.Y. Carbajo18, D. Carpio19, C. González-Muñoza20, F. Gomollón21, J.M. Huguet22, M. Rivero23, E. Iglesias-Flores24, M. Sierra25, L. Hernández-Villalba26, E. Domènech27, J.P. Gisbert1

Created: Thursday, 30 January 2020, 10:12 AM
P434: Close rectal versus total mesorectal excision in patients with inflammatory bowel disease undergoing proctocolectomy or completion proctectomy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. de Groof*, O. van Ruler, P. Tanis, W. Bemelman, C. Buskens

Created: Friday, 22 February 2019, 9:49 AM
P434: Factors associated with medical and psycosocioeconomic changes in IBD during the COVID-19 pandemic and post-pandemic period
Year: 2021
Source: ECCO'21 Virtual
Authors: Hu, S.(1);Wang, X.(1);Shen, B.(2);Yu, Q.(1);Zheng, J.J.(3);Chen, Y.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P434: Joint Inflammatory Bowel Disease–Obstetric clinics: outcomes in 95 pregnancies at a tertiary centre over a 3-year period
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Chew T.S.*1, Carmichael M.S.1, Hoare T.W.2, Waugh J.3, Gunn M.C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P434: Remission induction in corticosteroid naive children and adolescents with active ulcerative colitis by adsorptive leucocytapheresis after failure of first-line medications: Results from routine clinical practice
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Tanaka*, M. Akagi, H. Goishi, T. Iiboshi, T. Kajihara, T. Miura

Created: Thursday, 21 February 2019, 9:14 AM
P434: Surgery management of Crohn's disease in children: our experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Pujol Muncunill*1, J. González Pérez1, L. Saura García2, A. I. Pascual Pérez1, V. Vila Miravet1, X. Tarrado Castellarnau2, J. Martin de Carpi1

Created: Friday, 22 February 2019, 9:41 AM
P434: The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Dignass, A.U.(1);Gisbert, J.P.(2);Bossa, F.(3);Freudensprung, U.(4);Addison, J.(5);
Created: Friday, 11 February 2022, 3:52 PM
P434: Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn's disease: Results from induction and maintenance phase 3 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ghosh, S.(1)*;Feagan, B.(2);Parra, R.S.(3);Lopes, S.(4);Steinlauf, A.(5);Kakuta, Y.(6);Joshi, N.(7);Lee, W.J.(7);Remple, V.(7);Lacerda, A.P.(7);Zhou, Q.(7);Xuan, S.(7);Louis, E.(8);
Created: Friday, 14 July 2023, 11:05 AM